/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting.
Humanigen Shares Rise on Completing Phase 1 Brain Cancer Trial Enrollment Source:
Streetwise Reports (12/17/20) Shares of Humanigen Inc. traded 24% higher after the company reported that it had successfully completed enrollment of patients in a Phase 1 Study of ifabotuzumab in glioblastoma multiforme.
Clinical stage biopharmaceutical company Humanigen Inc. (HGEN:NASDAQ), which is focused on developing therapies for treating cancer and infectious diseases, today announced that it is completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM).
The firm explained that its proprietary ifabotuzumab is an anti-EphA3 monoclonal antibody. Humanigan noted that it has received funding for the study from the Cure Brain Cancer Foundation and that the trial is being conducted at the Olivia Newton-John Cancer Research Institute in Heidelberg, Victoria, Australia. The company stated that it expects to